Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Lung Neoplasms 9Brain Neoplasms 7NSCLC 3Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non-Small-Cell Lung 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × icotinib × Clear all
NCT02362230 2021-01-29

Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Sun Yat-sen University

Phase 2 Terminated
26 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡